A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically higher ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

H.C. Wainwright updated AnaptysBio’s model to include $75M in milestones from GSK to the company in 2026 for $1B in annual sales of Jemperli. In addition, it increased estimates for ...

Reports Q4 revenue $43.11M, consensus $7.79M. The increase in non-cash revenue in 2024 is due to $15M and $25M commercial milestones earned for ...

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an ...